Nuveen LLC Makes New $2.34 Million Investment in Dyne Therapeutics, Inc. $DYN

Key Points

• Nuveen LLC has acquired a new stake in Dyne Therapeutics, purchasing approximately 223,215 shares valued at around $2.34 million, representing about 0.20% of the company's shares.
• Several hedge funds, including Vanguard Group and Janus Henderson Group, have recently increased their holdings in Dyne Therapeutics, suggesting growing interest among institutional investors.
• The company's stock ratings are generally positive, with a consensus "Buy" rating from analysts and a notable drop in price targets from various firms reflecting recent market adjustments.

Nuveen LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 223,215 shares of the company's stock, valued at approximately $2,335,000. Nuveen LLC owned about 0.20% of Dyne Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of DYN. China Universal Asset Management Co. Ltd. boosted its position in shares of Dyne Therapeutics by 5.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after buying an additional 1,115 shares during the period. Arizona State Retirement System increased its holdings in shares of Dyne Therapeutics by 9.2% during the first quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after purchasing an additional 1,481 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Dyne Therapeutics in the fourth quarter worth about $50,000. GAMMA Investing LLC raised its position in shares of Dyne Therapeutics by 837.5% during the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after buying an additional 2,345 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its stake in shares of Dyne Therapeutics by 1.5% during the fourth quarter. Rafferty Asset Management LLC now owns 167,482 shares of the company's stock valued at $3,946,000 after acquiring an additional 2,520 shares during the period. Institutional investors and hedge funds own 96.68% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DYN. Evercore ISI reaffirmed an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Sanford C. Bernstein assumed coverage on Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective for the company. Royal Bank Of Canada dropped their price target on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 29th. Chardan Capital dropped their price objective on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, July 29th. Finally, Oppenheimer decreased their price objective on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating on the stock in a report on Wednesday, August 6th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $34.07.

Insiders Place Their Bets

In other news, CEO John Cox purchased 100,000 shares of the business's stock in a transaction on Monday, July 14th. The shares were acquired at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares in the company, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 20.77% of the company's stock.

Dyne Therapeutics Stock Performance

Shares of DYN stock traded down $0.10 on Wednesday, hitting $13.40. The company's stock had a trading volume of 1,115,413 shares, compared to its average volume of 2,630,842. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $37.08. The stock's 50 day moving average is $10.57 and its 200-day moving average is $11.15. The company has a market capitalization of $1.91 billion, a PE ratio of -3.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.